Compare EXEL & MOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXEL | MOH |
|---|---|---|
| Founded | 1994 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 8.9B |
| IPO Year | 2000 | 2003 |
| Metric | EXEL | MOH |
|---|---|---|
| Price | $43.87 | $133.95 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 13 |
| Target Price | $46.60 | ★ $185.00 |
| AVG Volume (30 Days) | ★ 2.7M | 2.2M |
| Earning Date | 02-10-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.95 | N/A |
| EPS | 2.78 | ★ 8.92 |
| Revenue | $2,320,126,000.00 | ★ $43,563,000,000.00 |
| Revenue This Year | $14.86 | $7.91 |
| Revenue Next Year | $14.93 | $8.13 |
| P/E Ratio | $15.36 | ★ $14.21 |
| Revenue Growth | 6.98 | ★ 11.23 |
| 52 Week Low | $32.38 | $121.06 |
| 52 Week High | $49.62 | $359.97 |
| Indicator | EXEL | MOH |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 29.59 |
| Support Level | $40.92 | $121.06 |
| Resistance Level | $44.28 | $185.40 |
| Average True Range (ATR) | 1.48 | 7.41 |
| MACD | 0.03 | -6.88 |
| Stochastic Oscillator | 70.53 | 15.17 |
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Molina provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in just four states—California, New York, Texas, and Washington—account for over half of its enrollees.